Natural rodent model of viral transmission reveals biological features of virus population dynamics
Emerging viruses threaten global health, but few experimental models can characterize the virus and host factors necessary for within- and cross-species transmission. Here, we leverage a model whereby pet store mice or rats-which harbor natural rodent pathogens-are cohoused with laboratory mice. Thi...
Saved in:
Published in | The Journal of experimental medicine Vol. 219; no. 2 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Rockefeller University Press
27.12.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Emerging viruses threaten global health, but few experimental models can characterize the virus and host factors necessary for within- and cross-species transmission. Here, we leverage a model whereby pet store mice or rats-which harbor natural rodent pathogens-are cohoused with laboratory mice. This "dirty" mouse model offers a platform for studying acute transmission of viruses between and within hosts via natural mechanisms. We identified numerous viruses and other microbial species that transmit to cohoused mice, including prospective new members of the Coronaviridae, Astroviridae, Picornaviridae, and Narnaviridae families, and uncovered pathogen interactions that promote or prevent virus transmission. We also evaluated transmission dynamics of murine astroviruses during transmission and spread within a new host. Finally, by cohousing our laboratory mice with the bedding of pet store rats, we identified cross-species transmission of a rat astrovirus. Overall, this model system allows for the analysis of transmission of natural rodent viruses and is a platform to further characterize barriers to zoonosis. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Disclosures: S.V. Kotenko reported a patent to IFN-λ polypeptides and compositions issued, a patent to IFN-λ1 polypeptides issued, a patent to method for increasing IFN activity in an individual issued, a patent to methods for increasing levels of IFN activity with an IFN-λ3 polypeptide issued, and a patent to type I and type III IFN fusion molecules and methods for use thereof pending. No other disclosures were reported. E.J. Fay, K.M. Balla, S.N. Roach, and F.K. Shepherd contributed equally to this paper. |
ISSN: | 0022-1007 1540-9538 |
DOI: | 10.1084/jem.20211220 |